Review

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma

Ahmad Ali 1,†, Ugo Chianese 1,†, Chiara Papulino 1,*, Chiara Papulino 1, Antonella Toraldo 1, Mawada Elmagboul Abdalla Abakar 1, Eugenia Passaro 1, Rosario Cennamo 1,2, Nunzio Del Gaudio 1, Lucia Altucci 1,3,‡ and Rosaria Benedetti 1,*,‡

1 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
2 AORN Chirurgia d’Urgenza, Ospedale Cardarelli, 80131 Naples, Italy
3 Biogem Institute of Molecular and Genetic Biology, 83031 Ariano Irpino, Italy
* Correspondence: rosaria.benedetti@unicampania.it; Tel.: +39-081-566-7566
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Simple Summary: The survival of organic systems is dependent on metabolic conditions, necessary for the proper functioning of all biological processes. Cancer takes advantage of altered bioenergetic circuits to improve its chances of growth, and pancreatic ductal adenocarcinoma is no exception. In this review, we describe the metabolic features of pancreatic ductal adenocarcinoma and discuss how this dependency could be exploited as a weakness for clinical interventions.

Abstract: Metabolism plays a fundamental role in both human physiology and pathology, including pancreatic ductal adenocarcinoma (PDAC) and other tumors. Anabolic and catabolic processes do not only have energetic implications but are tightly associated with other cellular activities, such as DNA duplication, redox reactions, and cell homeostasis. PDAC displays a marked metabolic phenotype and the observed reduction in tumor growth induced by calorie restriction with in vivo models supports the crucial role of metabolism in this cancer type. The aggressiveness of PDAC might, therefore, be reduced by interventions on bioenergetic circuits. In this review, we describe the main metabolic mechanisms involved in PDAC growth and the biological features that may favor its onset and progression within an immunometabolic context. We also discuss the need to bridge the gap between basic research and clinical practice in order to offer alternative therapeutic approaches for PDAC patients in the more immediate future.

Keywords: PDAC; metabolism; glucose; amino acids; lipids; immune response

1. Introduction

The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing in recent years and is expected to become the second-leading cause of cancer death by 2030 [1]. PDAC is an aggressive tumor, often diagnosed at an advanced stage due to the lack of symptoms [2,3]. PDAC is not always treatable with surgery and, in fact, only 20% of patients have resectable disease [4,5]; similarly, chemotherapy treatments are poorly effective. In a cohort of 136 patients, 74.3% experience relapse within one year, while 25.7% was found to recur within the first six months of surgery [6]. Next-generation sequencing (NGS) technologies analyzing the mutational profile of PDAC patients recently identified mutations occurring at early or late stages of the disease [7]. KRAS, detected in 90% of cases as mutated and/or amplified [8], is chronologically the first mutated gene in pancreatic intraepithelial neoplasia (PanIN) lesions [9], precancerous stage. The second-most-commonly mutated gene in PDAC is TP53, predominantly presenting missense mutations [10] associated with a very poor outcome [11]. Another common mutant gene in PDAC is CDKN2A, encoding a cyclin-dependent kinase inhibitor, resulting in loss-of-function alterations; a
lower degree of differentiation of PDAC cells was related to a more rapid CDKN2A degradation [12]. SMAD4 mutations occur in late stages of PDAC and seem to be linked to its inactivation in approximately 50% of pancreatic cancer cases, promoting tumor growth and metastasis [13] and representing an increased risk factor for overall survival [14]. The main classification of pancreatic cancer distinguishes between exocrine and neuroendocrine tumors [15,16]. The vast majority of cases (95%) are exocrine pancreatic cancers, including PDAC, which accounts for more than 90%, and acinar cell carcinoma, which makes up 1–2%. Neuroendocrine cancers are rare, comprising less than 5% of all pancreatic cancers [17]. PDAC is often associated with other metabolic comorbidities, such as obesity and diabetes, which occur in 15–35% of PDAC patients and are considered risk factors [18–20]. Algorithms and prediction models were developed to identify high-risk patients among a large number of obese and diabetic patients [21]. Some antidiabetic medications, such as metformin, may decrease the risk of PDAC [22], while others, including insulin, are associated with an increased risk [23]. The fact that PDAC exhibits a marked metabolic phenotype (Figure 1) suggests that the metabolic environment may play a key role [24]. PDAC has high energy requirements, which are met through the rewiring of cell metabolism. Nutrients are, therefore, consumed to provide energy, ensure biosynthesis, and minimize oxidative stress. PDAC exploits metabolic pathways to sustain rapid cell proliferation [25], thereby depleting major nutrients in the tumor microenvironment and adversely affecting other cell types, in particular, immune, acinar, and ductal cells [26]. PDAC cells are surrounded by immune cells, stellate cells, cancer-associated fibroblasts, and extracellular matrix (ECM) [27,28]. According to their metabolic profile, PDAC cells are divided into three metabolic subtypes: slow proliferating, glycolytic, and lipogenic [29]. Metabolic plasticity also makes a major contribution to cancer heterogeneity [30]. Single-cell RNA sequencing analysis identified distinct types of ductal cells according to their gene expression profiles based on PDAC heterogeneity [31]. A common subtype of ductal cells was found in both healthy and cancerous tissues, while a second subtype, showing altered energy distribution, was found to reside in PDAC tumors [32]. PDAC is also associated with inflammatory states, which contribute to its progression [33]. Furthermore, inflammation has been linked to the immunometabolic context, since pro-inflammatory stimuli may induce a metabolic switch in hematopoietic cells, increasing aerobic glycolysis similarly to the Warburg effect [34], the well-known shift to aerobic glycolysis (lactate production) in the presence of oxygen [35]. Single-cell sequencing suggests that macrophages, T cells, and fibroblasts are highly heterogeneous within the tumor microenvironment [36] and are strongly affected by its metabolic context [37]. In vivo mouse experiments revealed that macrophages exhibited elevated glycolysis and that macrophage-specific deletion of GLUT-1 reduced tumor burden by increasing natural killer and CD8+ T cell activity and suppressing the inflammatory state [38]. Glutamine antagonists are also reported to induce a change in the antitumor immune response by converting a “cold” tumor microenvironment into a “hot” one, eliciting significant responses to anti-PD1 therapy, a cell surface protein involved in the suppression of the immune system [39]. Taking all these findings together, it seems clear that metabolites play a crucial role in homeostasis and tumor progression. The analysis of metabolic turnover in the tumor microenvironment is, therefore, key to defining the energy phenotype and metabolic landscape of PDAC.
Figure 1. Metabolic landscape in PDAC. (1) To promote glucose uptake in PDAC cells, KRAS and HIF1 upregulate the GLUT family of genes and other genes associated with glycolysis. While a portion of the glycolytic cascade is used to fuel oxidative phosphorylation and the production of ATP, or alternatively to promote lactate, which helps to create an acidic microenvironment, another branch of the process is directed toward the PPP pathway to provide precursors for nucleotide and amino acid biosynthesis. (2) Cellular redox homeostasis and energy generation are both regulated by amino acid metabolism. Glutamine is transformed into glutamate and aspartate, which are then transported to the mitochondria to maintain redox balance. (3) Citrate is shuttled from the mitochondria into the cytoplasm to stimulate the de novo lipid synthesis pathway, and at the same time, redox processes are balanced by NADPH–NADP⁺ conversion. This process activates the lipid synthesis pathway. In addition, exogenous lipid intake is boosted to meet the need for nutrients for rapid proliferation. (4) Different metabolites/nutrients, such as Ala and Pro, generated from collagen degradation or PSC secretion and transformed into pyruvate, are supplied to PDAC cells by the tumor microenvironment.

2. Metabolic Reprogramming of the Main Energy Pathways in PDAC

2.1. Activation and Maintenance of Glycolytic Flux

In PDAC, the expression of glycolytic genes is regulated at both the transcriptional and post-transcriptional level via oncogenic KRAS [40]. KRAS signaling plays a crucial role in regulating transcription of both glucose transporters (GLUTs) and key glycolysis genes [41]. Glucose’s need of the PDAC system seems to be due to the expression of facilitated GLUTS and sodium–glucose transporter (SGLTs); PDAC tumors showed both increased pyruvate carboxylation and glucose oxidation via pyruvate dehydrogenase in vivo [42]. PDAC progression is induced by the activation of mutant KRAS, resulting in an increase in GLUTs, such as GLUT-1, from low- to high-grade dysplasia. Oxygen is related to GLUT-1 expression through hypoxia-inducible factor 1 alpha (HIF-1α). In patients with low-expression levels of GLUT-1, neoadjuvant chemotherapy, such as TS-1, showed better therapeutic response and better prognosis than in those with higher GLUT-1 expression levels [43]. PDAC tumor biology relies on hypoxia and HIF1α signaling to control tumor-promoting stromal programs, which facilitate progression and tumor cell invasiveness [44]. Hypoxia-activated stromal cells contribute to the invasive growth of PDAC cells by releasing soluble proteins, such as MMP10, and enhance the levels of inflammatory and angiogenic factors, including IL1α, TIE family members, and VEGF-A. MMP10, the main stromal protein driving EMT in tumor cells [45], is reported as a stellate cell product [46], [47]. IL1α was shown to be released by both stromal cells and PDAC cells, thus, promoting tumor growth [48] in
an autocrine manner [49] and stimulated the fibrotic component [50]. TIE1 upregulation and increased TIE2 transcription in hypoxic stellate cells are crucial for the remodeling and maturation of tumor vasculature [51], forming a complex with angiopoietins and sustaining TIE2 signaling in contacting cells [52]. Altered levels of VEGF-A found in PDAC indicate an imbalance in normal angiogenetic processes [53]. In particular, the high extracellular matrix component associated with vasculature collapse resulted in an increased hypoxic environment, partly explaining the low efficacy of antiangiogenic drugs in this cancer [54] and the inefficient delivery of chemotherapeutic agents [55], thus, emphasizing a recently described stroma-targeting therapy that aims to reduce the stromal component to improve target achievement [56]. According to the transcriptomic profiles of PDAC patients, ubiquitin specific peptidase 25 (USP25) depletion was linked to decreased levels of HIF-1α, GLUT-1, and glycolysis signaling. This suggests that the USP25 complex deubiquitinates and stabilizes the HIF-1α transcription factor from a mechanistic point of view [57]. SGLTs also play a functional role in glucose uptake, since the selective inhibition of SGLT2 in mouse models of pancreatic cancers led to a decrease in glucose uptake [58]. Furthermore, the hypoxic environment is essential for maximizing energy yield and biomass production, which are ensured by the lack of oxygen, which promotes conversion of pyruvate into lactate, by Lactate Dehydrogenase A [59]. In this way, ATP is generated and an increased amount of lactic acid is released outside of the cell, acidifying the microenvironment and, in turn, facilitating PDAC progression [60]. Monocarboxylate transporters (MCTs), which transport lactate, are abundantly expressed in PDAC [61]. MCT1 and MCT4 regulate lactate efflux through KRAS-dependent signaling, releasing intracellular accumulated lactate and maintaining intracellular pH [62]. This process facilitates the oxidation of nicotinamide adenine dinucleotide (NADH) to NAD+, a cofactor for oxidizing glyceraldehyde 3-phosphate and driving glycolysis [63]. The glycolytic shift meets the energy demands required for tumor growth, as well as supplying the building blocks for biochemical reactions and intermediates [64]. MUC1 and MUC13 transporters also stabilize transcription of HIF-1α during hypoxia conditions and induce the expression of glycolytic genes [65] associated with poor survival rates in PDAC patients [57]. In contrast, CD147 works as a chaperone for the membrane localization of MCT1 and MCT4, both expressed in PDAC cells [66]. Whether the interaction between CD147 and MCT is related to PDAC progression has not yet been determined [67]; however, depletion of MCT4 reduces cell viability, whereas depletion of CD147 affects tumor growth in xenograft models [62,68]. As regards the glycolytic flux of anabolic pathways in PDAC, the pentose phosphate pathway (PPP) is a branch of glycolysis that directs glucose flux to oxidation and regulates NADP and nucleic acid synthesis, which ensure fatty acid (FA) production and cell survival under stress conditions [69]. According to a metabolomic analysis of PDAC, the adaptation to acidosis status increases glucose and decreases glycolysis, driving a shift to PPP [60,70]. PPP occurs in two different ways: oxidatively and non-oxidatively. The oxidative arm transforms glucose 6-phosphate into ribulose-5-phosphate and CO2, which are essential for maintaining redox equilibrium under stress conditions [71]. The non-oxidative branch produces glycolytic intermediates, resulting in the production of sugar phosphate, an important precursor for amino acid synthesis, ribose-5-phosphate, which is needed for nucleic acid synthesis [72]. Furthermore, oncogenic KRAS selectively activates non-oxidative PPP, possibly via the induction of genes involved in the non-oxidative arm, such as ribulose-5-phosphate isomerase (RPIA) [73]. Low expression levels of RPIA deficits result in reduced KRAS-driven signaling in PDAC cells, indicating the importance of non-oxidative PPP in metabolic function [40]. Growing evidence suggests that non-oxidative PPP contributes to gemcitabine resistance in PDAC and that reduced expression of transketolase is associated with higher gemcitabine sensitivity in PDAC patients, strengthening the therapeutic potential of targeting non-oxidative PPP [65]. Post-transcriptional processes, such as those modulated by microRNAs, are also thought to play an important role in PDAC progression [74]. microRNAs are linked to the regulation of glycolysis in PDAC; the tumor suppressor miR-124 regulates MCT1 [75], resulting in
increased intracellular pH that reduces the acidic environment and decreases PANC-1 cell proliferation. miR-135 was found significantly overexpressed in PDAC patient samples compared to normal tissue and, notably, was associated to a metabolic alteration. miR-135 accumulation during glutamine deprivation has been observed, promoted by mutant TP53. Specifically, miR-135 targets phosphofructokinase-1, inhibiting aerobic glycolysis and promoting TCA cycle [74]. Some studies have already been conducted on the potential role of miRNA as biomarkers of PDAC. miRNA-483-3p and miRNA-21 were found to be significantly higher from blood plasma in PDAC compared to healthy controls and related to advanced-stage disease [76,77]. Further functional studies on miR-124 may lead to new therapeutic strategies for PDAC [75].

2.2. Amino Acids as an External Energy Resource

The PDAC phenotype is also triggered by the rewiring of amino acids, contributing to the metabolic profile of PDAC by regulating cell proliferation, invasion, and redox homeostasis [78]. In cellular hemostasis, glutamine is a multifunctional amino acid that serves as a key energy source [79]. The biological activities of glutamine range from providing energy to stabilizing reducing agents, contributing to the biosynthesis of purines and pyrimidines, and its involvement in PDAC has been recognized [80,81]. PDAC cells can compensate for the increased metabolic demand either by increasing glutamine production or by increasing glutamine uptake from the environment, thus, reducing glutamine levels in blood serum, despite the abundance of fibrotic cells in the pancreas [82]. Glutamate–Ammonia Ligase (GLUL), the enzyme responsible for de novo production of glutamine, was found elevated in PDAC [83]. Although the cause of this increase is not completely clear, CRISPR/Cas9 ablation of GLUL in PDAC mouse models reduced tumor growth [83]. Metabolic niches also contribute significantly to cancer development and progression. Autophagy plays a pivotal role in supporting the growth of PDAC through fibroblasts [84]. Autophagy allows fibroblasts to break down misfolded proteins and ECM, releasing large quantities of amino acids into the microenvironment [85]. In addition, circulating macromolecules enter PDAC cells using the Na+-dependent glutamine transporter SLC1A5, in the case of glutamine, or via macropinocytosis/micropinocytosis, for proteins, a mechanism linked to the growth of cancer cells expressing oncogenic KRAS [86–89]. Micropinocytosis inhibitors were found to interfere with this ability in MIAPaCa2 cells, a PDAC model [90]. Glutamate intake is converted into glutamate to feed a complex network of enzymes and intermediates. PDAC utilizes glutamate to activate the tricarboxylic acid (TCA) cycle and electron transport chain after its conversion into alpha-ketoglutarate (αKG) in mitochondria; notably, αKG acts as an epigenetic factor [91]. αKG may also function in a TCA-independent manner by acting as a cofactor for dioxygenases [91], controlling gene expression, DNA methylation, and DNA damage reactivity [92]. Similar to glutamine, alanine is also required for metabolic homeostasis in PDAC and is derived from pancreatic stellate cells (PSCs) [93]. Several studies have investigated the unidirectional channeling of alanine between PSCs and PDAC [93,94]. SLC38A2 activity facilitates alanine uptake, although other transporters have been identified, including SLC1A4 [93]. PDAC cells also express the mitochondrial isoform of glutamic-pyruvic transaminase ALT2 for de novo synthesis and alanine utilization. The ratio between aspartate transaminase AST and alanine aminotransferase ALT was used to predict poor prognosis and response to gemcitabine/nab-paclitaxel treatment in PDAC patients [95]. In co-injection xenograft models, the beneficial support provided by stellate cells was disrupted by targeting SLC38A2, causing significant tumor regression in PDAC and affecting cytosolic alanine internalization and concentration [93]. PDAC can also use proline as a fuel source and this energy comes from collagen that is largely found in the ECM [96]. Proline degradation by the mitochondrial enzyme PRODH1 is an active factor in PDAC cell proliferation, both in vitro and in vivo [96], indicating that ECM is an important nutrient reservoir for cancer cell metabolic flexibility. Some context-specific metabolic mechanisms have also been described for PDAC, such as the TP53-mediated overexpression of SLC1A3, an Na+/K+/H+-dependent aspartate/glutamate transporter, which enables the aspartate
metabolism to maintain cancer cell survival and tumor growth under conditions of glutamine starvation [97]. By perturbing glutamine metabolism, redox homeostasis proteins are deregulated, leading to reactive oxygen species ROS accumulation, which then leads to a cellular redox imbalance facilitating PDAC cell apoptosis [98]. Pharmacological and genetic targeting of nicotinamide phosphoribosyltransferase (Nampt), a key redox enzyme, inhibited cell growth and survival of PDAC cells in vitro and in vivo [99]. Other findings link amino acids with cell fate. KRAS-driven PDAC mouse models were less responsive to a depletion of serine and glycine [100]. Cysteine depletion induced ferroptosis in KRAS/TP53 mutant pancreatic tumors in mice, and the disruption of amino acid pathways was able to enhance gemcitabine chemosensitivity in drug-resistant PDAC [98,101]. Ferroptotic damage can result in the release of damage-associated molecular pattern molecules, which can lead to inflammation [102].

2.3. Fatty Acids Contribute to PDAC Progression

Epidemiological studies correlated PDAC with dyslipidemia [103], showing an altered biosynthesis of cholesterol and other lipids in murine PDAC cells [104–107]. Lipogenic enzymes are frequently overexpressed in PDAC, supporting their potential contribution to tumor growth [108]. Alanine from PSCs can be taken up by PDAC cells and used for FA biosynthesis. Serum FA synthase (FASN) levels are, in fact, generally higher in PDAC patients [109] as a result of SREBP1 activity [110] and are associated with lower survival than in patients with low FASN expression and with poor response to gemcitabine [111,112]. Once again, driver mutations in KRAS and loss of function in TP53 reprogram metabolism accelerate cholesterol biosynthesis and uptake [40], mediating metabolic plasticity via SREBP1-dependent regulation of transforming growth factor-β expression involved in PDAC differentiation [105]. Oncogenic KRAS regulates hormone-sensitive lipase (HSL) to control metabolism by regulating lipid storage and utilization (specifically through suppression of HSL expression), leading to lipid droplet (LD) accumulation and priming tumor cells for invasion [113]. Perilipins constitute the major proteins resident on LD surface controlling intracellular lipid homeostasis [114,115]. Perilipin 2 (PLIN2) was found overexpressed in a cohort of 181 PDAC patients [116] and was associated with poor MFS, DFS, and OS rates, as well as with poor prognosis. Further investigations using an in vivo mouse model showed that exposure of pancreatic β cells to fatty acids stimulated PLIN2 expression, impacting on cellular stress, whereas its ablation prevented fatty-acid-induced TG accumulation [115], mitigating stress and leading to a significant improvement in hyperglycemia [117]. Notably, PLIN2 is expressed in other cell types, such as monocytes and macrophages [118], where its expression was positively correlated with LGALS9 in PDAC; this protein converts polarized macrophages into an M2 phenotype, leading to the inhibited secretion of T-cell cytokines [119]. These findings suggest that PLIN2 might participate in immunomodulatory effects by regulating tumor-associated macrophages in the tumor microenvironment [120]. A high-fat diet was able to ameliorate mutated KRAS activity, increasing fibrosis and enhancing PDAC progression in a mouse model [121], and a recent study with an in vivo mouse model showed a causal and positive correlation between obesity and early PDAC progression, identifying altered beta cell expression of cholecystokinin (Cck) in response to obesity and defining islet Cck as a promoter in oncogenic KRAS-driven PDAC [122]. LDs are recognized as important regulators in cancer; these dynamic intracellular organelles are used for cellular storage of lipids, such as triacylglycerol and cholesterol ester [123]. Lipids can, thus, be catabolized by lipolysis via lipases to liberate free FAs [124], causing increased FA oxidation and oxidative metabolism, which drives tumor cell invasion. Low-density lipoprotein receptor (LDL-R) is highly expressed in PDAC and is associated with increased PDAC recurrence [125]. LDL-R increases cholesterol uptake, while its inhibition reduces proliferation, affecting ERK1/2 survival pathway, and sensitizes PDAC cells to chemotherapeutic drugs, favoring tumor regression [125]. Interestingly, mutated KRAS is able to control the sequestration of extracellular unsaturated FAs [126]. ACSL3 activity, a protein-coding gene for a member of Acyl-CoA synthetase
long-chain family, has been linked to KRAS-mutated tumors [127] and associated with the retention of extracellular unsaturated FAs by converting them into esters that remain confined in PDAC cells [128,129]. Serum lipid depletion or ACSL3 inhibition decreased tumor cell proliferation, provoking a rebound effect due to lipid restriction that was balanced by increased autophagic flux, in both in vitro and in vivo models [130]. Notably, combining lipid depletion with autophagy inhibitors induced the most potent effect, with arrest of PDAC proliferation and increased apoptosis [130]. Recently, metabolomic profiles clarified key aspects of the metabolic signature of pancreatic cancer stem cells (PCSCs) originating from PDAC cells, revealing a fundamental role for the pyruvate–malate cycle and lipid metabolism in their survival [131]. While lipidomic analysis suggested a strong induction of long-chain FAs and accumulation of LDs mediated by ELOVL5, a fatty acid elongase, other data highlighted cardiolipin acyl-chain composition as pivotal in PCSCs [132]. Changes in cardiolipin composition have an impact on enzymes involved in the respiratory process and integrity of the inner membrane [133,134], indicating that cardiolipin plays a critical role in oxidative phosphorylation. A comprehensive investigation on serum lipids of 830 PDAC samples by mass spectrometric determination revealed statistically significant differences between PDAC patients and healthy controls [135]. While a lysophosphatidylcholine LPC 18:2 was positively correlated with survival, Cer 36:1, Cer 38:1, Cer 42:2, PC 32:0, PC O-38:5, and SM 42:2 were inversely correlated, suggesting their potential role as prognostic biomarkers. Other data in PDAC tissues by MALDI-MSI analyses indicated that LPC (16:0, 18:1), as reported for other LPCs [136,137], and DAG 36:2 were decreased, while PC 32:0, SM d36:1, and SM d42:3 were increased [138]. Glycerophospholipid and sphingolipid metabolism pathways were also found dysregulated in PDAC [138]. Regarding lipid saturation degree, polyunsaturated phosphatidylcholines were reduced in serum of PDAC [139]. It is tempting to speculate that this altered profile might reflect apoptotic resistance in PDAC, given that polyunsaturated FAs, via peroxidation, act as substrates for ferroptosis in cell membranes [140,141].

3. Immune Cells and Metabolic Response in PDAC Microenvironment

Immune cell functionality and metabolism are closely linked and are able to influence each other [142]. In recent years, several studies provided compelling evidence that changes in cellular metabolism affect immune cell function (Figure 2), which, in turn, impacts cell metabolism [142,143] due to competition for nutrients. The high energy demands of tumor cells cause nutrient depletion, resulting in decreased rates of glycolysis in tumor-infiltrating lymphocytes [144,145]. The imbalance in metabolic profile and chronic inflammation can trigger autoreactivity and ultimately disrupt protective immunity. Several immunosuppressive cytokines were found to cause tumor development by impairing cytotoxic and helper T cells [146]. The acid environment created by lactic acid levels inhibited cytotoxic T cell function, promoting tumor growth [147]. In addition, immunohistochemistry analysis detected an increase in CD8+ and CD4+ T cells, leading to a better outcome in PDAC patients [148,149]. In PDAC, CD8+ T-cell activity is altered due to degradation via MHC-I, member of the histocompatibility complex [150], while inhibition of autophagy restores surface levels of MHC-1, enhancing anti-tumor T-cell response, improving [151] clinical outcomes, increasing the survival rate for PDAC patients [152]; the effect observed in CD4+ T cells depends on their subtype differentiation [153]. T-helper 1 cells contributed to a positive clinical outcome via IFN-γ and TNF-α production, promoting anticancer activities through cytotoxic T-cell response [154,155]. Interestingly, insulin receptors are expressed on activated CD4+ T cells and can contribute to reshaping the adaptive immune system by regulating T-cell metabolism [156]. Induced knockdown of insulin receptors led to a reduced glucose metabolism and cytokine production in T cells [157]. Glutamine may also act as a regulator of effector and regulatory T-cell (Treg) balance in the PDAC microenvironment, reducing Th17 and Th1 cells and promoting the development of Tregs [158]. The production of αKG by glutamate dehydrogenase promotes cancer growth and interferes with immune response, acting as an anaplerotic intermediate in the TCA cycle and providing nitrogen for
non-essential amino acid synthesis [81]. T cells need arginine and tryptophan for activation to generate memory T cells by switching from glycolysis to oxidative phosphorylation, thus, promoting tumor arrest [159]. PDAC is thought to be fueled by a feed-forward mechanism, in which amino acid intermediates support cancer growth by depleting arginine and tryptophan, inhibiting T-cell proliferation and promoting Treg differentiation [160]. Indeed, Tregs can inhibit immune responses mediated by T cells, as described in a study involving a total of 100 patients with PDAC [161]. The authors evaluated the prevalence of Tregs in peripheral blood mononuclear cells from patients in relation to their clinical outcomes and showed that the percentage of Tregs in the patients with PDAC was significantly lower than in healthy volunteers. Additionally, numbers of mast cells from 103 patients with PDAC and 10 patients with a normal pancreas were investigated about their distribution PMID: 21167541 [162]. Results showed a zone-specific distribution of mast cells in PDAC, highlighting the importance of invasive front in the prognosis of patients with PDAC after curative resection. Dendritic cells are an integral part of the PDAC tumor microenvironment, characterized by a reduced number compared to the healthy condition, which impacts antigen presentation and contributes to immune tolerance [163]. Macrophages have also been linked to the immunometabolic context in PDAC. In response to the environment conditioned by PDAC, macrophages switch from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype [164,165]. M1 macrophages showed an enhanced glycolytic and lipolytic activity [166], promoted by fructose-2,6-bisphosphatase enzyme [167]. Furthermore, when PPP is inhibited, macrophages switch toward an anti-inflammatory state, increasing TCA cycle and FA oxidation [168–170].

Figure 2. T-cell and macrophage activity in the PDAC-conditioned environment. (a) [154,169]; (b) [171]; (c) [148,172]; (d) [164]; and (e) [173].

4. Clinical Perspectives

Over the last decade, it has become clear that rapidly proliferating systems, such as cancer, use metabolism to facilitate cell survival and maintain growth [174]. Metabolic plasticity contributes to PDAC heterogeneity and although not all metabolic dependencies of pancreatic tumors have been revealed, some distinct phenotypes, such as the glycolytic
and lipogenic subtypes, have been identified. As a consequence, potentially innovative strategies to treat patients with PDAC are based on glycolytic and glutamine inhibitors, which have shown efficacy for the glycolytic subtype, while the lipogenic phenotype is more sensitive to inhibitors of lipid biosynthesis. Currently, PDAC trials are mainly focused on immunotherapy and chemotherapy [174] and there are still few trials investigating cell metabolism. Here, we reported the clinical trials focused on metabolic evaluation in PDAC (Table 1), such as NCT05132244, that will investigate the feasibility to monitor and manage glucose levels in people with PDAC and the related impact. NCT04245644 aims to understand if regular use of statins and metformin can increase the rate of disease-free survival and overall survival in PDAC participants, before diagnosis, after surgery, and in a neoadjuvant treatment setting, and possible use as chemoprevention, while a large randomized study of 528 participants (NCT03504423) is evaluating the effect of CPI-613 (devimistat), a pyruvate dehydrogenase inhibitor, to determine its efficacy and safety in patients with metastatic PDAC. The aim of another study (NCT02201381) is to assess the effectiveness of a regimen of metabolic treatments for patients in order to determine the relationship between the degree of response and changes in biochemical markers. In a cohort of 207 participants, metformin, atorvastatin, doxycycline, and mebendazole will be administered to evaluate the effectiveness of heterogeneous classes of drugs. Pharmacologically, metformin improves insulin sensitivity and the oxidative disposal of glucose and lactate. NCT04862260 will investigate the effect on cholesterol disruption also in metastatic PDAC patients (Figure 3). Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the metabolic pathway, producing cholesterol and other isoprenoids, thereby blocking lipid flow. Glycolytic and oxidative metabolisms can both be altered by doxycycline, while the carbohydrate metabolism can be affected by mebendazole. Devimistat already showed antitumor activity in xenograft mouse models of human colorectal cancer, enhancing therapeutic efficacy and preventing irinotecan-triggered p53 stabilization, making it a promising candidate to support antineoplastic therapy [175]. Other drugs for non-oncological use have shown off-label efficacy in PDAC, modulating proliferative arrest [176]. When drug targets, such as GLUT-1, were knocked out, a strong growth-inhibiting effect on PDAC biomass was observed, resulting in a no-growth phenotype [177].

Table 1. List of clinical trials for PDAC’s metabolic investigation (source https://clinicaltrials.gov/ accessed on 29 June 2022; Condition or disease: PDAC Pancreatic Ductal Adenocarcinoma and other terms: Metabolism.

| Identifier ID | Study Title | Conditions | Interventions |
|---------------|-------------|------------|---------------|
| NCT05296421  | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer | Primary | Procedure: Biopsy, Therapeutic Conventional Surgery Other: Uniformly-labeled [13C] glucose |
| NCT04565327  | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Patients With Locally Advanced or Metastatic Pancreatic Cancer | Primary | Drug: Hyperpolarized Carbon C 13 Pyruvate, Procedure: Magnetic Resonance Imaging (MRI) |
| NCT04862260  | Cholesterol Disruption in Combination With FOLFIRINOX in Patients With Metastatic Pancreatic Adenocarcinoma | Primary and Metastatic | Drug: Cholesterol metabolism disruption |
| NCT02978547  | The Effects of Neoadjuvant Metformin on Tumor Cell Proliferation and Tumor Progression in Pancreatic Ductal Adenocarcinoma | Primary | Drug: Metformin Hydrochloride 500 Mg Tablet |
| NCT05254171  | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Primary | Drug: SBP-101, Nab-paclitaxel, Gemcitabine and Placebo |
| NCT03450018  | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX | Metastatic | Drug: SLC-0111, Gemcitabine Injection |
Table 1. Cont.

| Identifier ID | Study Title                                                                 | Conditions       | Interventions                                                                                      |
|---------------|------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------------------------------|
| NCT05132244  | Monitoring and Managing Glucose Levels in People With Pancreatic Cancer       | Primary          | Procedure: Endocrinologist-directed target blood glucose level 4–10 mmol/L using data from a continuous glucose monitor (CGM). Other: Standard Care |
| NCT04915417  | Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma | Primary          | Radiation: Stereotactic Ablative Body Radiotherapy (SABR)                                          |
| NCT04662879  | Early Detection Initiative for Pancreatic Cancer                             | Primary          | Other: Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score. Other: Abdominal imaging |
| NCT03525392  | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumors Expressing Neurotensin Receptor Type 1. | Primary          | Drug: 177Lu-3BP-227 (also called 177Lu-IPN1087)                                                   |
| NCT03410030  | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | Primary          | Drug: Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine                            |
| NCT04245644  | Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study (CAOS) | Primary          | Behavioral: use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins |
| NCT03374852  | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | Primary          | Drug: CPI-613 Drug: mFOLFIRINOX                                                                 |

Figure 3. Mechanisms of action in cholesterol disruption. (1) Atorvastatin is a competitive inhibitor of HMG-CoA reductase, its inhibition decreases de novo cholesterol synthesis and increases expression of LDL receptors, removing LDL from the blood. (2) Evolocumab blocks PCSK9, a protein responsible for the breakdown of LDL receptors; this allows their overexpression facilitating LDL uptake from the blood. (3) Ezetimibe selectively inhibits the intestinal absorption of LDL.
5. Conclusions

Here, we discuss the metabolic profile of PDAC and its implications in terms of clinical outcomes. Blocking anabolic and catabolic processes is able to reduce PDAC progression, validating the plausible hypothesis that PDAC relies on metabolic reprogramming. Although the findings presented here identify metabolic processes as a potential target for this tumor, the translation of this approach to the clinic is slow, and clinical trials investigating metabolic reprogramming in PDAC are still few and far between. Exploring the metabolic landscape could lead to the development of innovative therapeutic strategies, increasing the chances of successful treatment and survival.

Author Contributions: Conceptualization, A.A. and U.C.; funding acquisition, L.A. and R.B.; Writing—original draft preparation, A.A., U.C., C.P., A.T. and E.P.; Images, M.E.A.A. and N.D.G.; Writing and editing, A.A., U.C. and R.C.; L.A. and R.B. are the last and corresponding authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Epi-MS under the VALERE 2019 Program; V:ALERE 2020—“CIRCE”; Campania Regional Government Technology Platform 2038 Lotta alle Patologie Oncologiche iCURE-B21C17000030007; Campania Regional Government FASE2: IDEAL; MIUR, Proof of Concept POC01_00043; “Nuovi Farmaci e Biomarkers di risposta e resistenza farmacologica nel Cancro del colon retto—NABUCCO 1682, MISE2020; POR Campania FSE 2014–2020 ASSE III; PON RI 2014/2020 “Dottorati Innovativi con caratterizzazione industriale”.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

Alpha-ketoglutarate (αKG); cholecystokinin (Cck); extracellular matrix (ECM); FA synthase (FASN); fatty acid (FA); glutamate-ammonia ligase (GLUL); glucose transporters (GLUTs); hormone-sensitive lipase (HSL); hypoxia inducible factor 1 alpha (HIF-1α); lipid droplet (LD); Low-density lipoprotein receptor (LDL-R); Monocarboxylate transporters (MCTs); Next-generation sequencing (NGS); nicotinamide adenine dinucleotide (NADH); nicotinamide phosphoribosyltransferase (Nampt); pancreatic ductal adenocarcinoma (PDAC); pancreatic cancer stem cells (PCSCs); pancreatic intraepithelial neoplasia (PanIN); pancreatic stellate cells (PSCs); pentose phosphate pathway (PPP); ribulose-5-phosphate isomerase (RPIA); sodium-glucose transporter (SGLTs); tricarboxylic acid cycle (TCA); ubiquitin specific peptidase 25 (USP25).

References

1. McGuigan, A.; Kelly, P.; Turkington, R.C.; Jones, C.; Coleman, H.G.; McCain, R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 2018, 24, 4846–4861. [CrossRef] [PubMed]
2. Rawla, P.; Sunkara, T.; Gaduputi, V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J. Oncol. 2019, 10, 10–27. [CrossRef]
3. Kamisawa, T.; Wood, L.D.; Itoi, T.; Takaori, K. Pancreatic cancer. Lancet 2016, 388, 73–85. [CrossRef]
4. Stathis, A.; Moore, M.J. Advanced pancreatic carcinoma: Current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7, 163–172. [CrossRef]
5. Stokes, J.B.; Nolan, N.J.; Stelow, E.B.; Walters, D.M.; Weiss, G.R.; de Lange, E.E.; Rich, T.A.; Adams, R.B.; Bauer, T.W. Preoperative capcitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann. Surg. Oncol. 2011, 18, 619–627. [CrossRef] [PubMed]
6. Sugawara, T.; Ban, D.; Nishino, J.; Watanabe, S.; Maekawa, A.; Ishikawa, Y.; Akahoshi, K.; Ogawa, K.; Ono, H.; Kudo, A.; et al. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. PLoS ONE 2021, 16, e0249885. [CrossRef] [PubMed]
7. Shen, G.Q.; Aleassa, E.M.; Walsh, R.M.; Morris-Stiff, G. Next-Generation Sequencing in Pancreatic Cancer. Pancreas 2019, 48, 739–748. [CrossRef] [PubMed]
8. Mueller, S.; Engleitner, T.; Maresch, R.; Zukowska, M.; Lange, S.; Kaltenbacher, T.; Konukiewitz, B.; Ollinger, R.; Zwiebel, M.; Strong, A.; et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 2018, 554, 62–68. [CrossRef]
9. Waters, A.M.; Der, C.J. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb. Perspect Med. 2018, 8, a031435. [CrossRef]
10. Scarpa, A.; Capelli, P.; Mukai, K.; Zamboni, G.; Oda, T.; Iacono, C.; Hirohashi, S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J. Pathol. 1993, 142, 1534–1543.
11. Maddalena, M.; Mallel, G.; Natraj, N.B.; Shreber-Shaked, M.; Hassin, O.; Mukherjee, S.; Arandkar, S.; Rotkopf, R.; Kapsack, A.; Lambiase, G.; et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. *Proc. Natl. Acad. Sci. USA* 2021, 118, e2025631118. [CrossRef]

12. Sikkad, N.; Saha, G.; Dutta, A.; Ghosh, S.; Shrikhande, S.V.; Banerjee, S. Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview. *Curr. Genom.* 2018, 19, 444–463. [CrossRef]

13. Bardeesy, N.; Cheng, K.H.; Berger, J.H.; Chu, G.C.; Pfahler, J.; Olson, P.; Hezel, A.F.; Horner, J.; Lauwers, G.Y.; Hanahan, D.; et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev.* 2006, 20, 3130–3146. [CrossRef]

14. Crane, C.H.; Varadhachary, G.R.; Yordy, J.S.; Staerkel, G.A.; Javle, M.M.; Safran, H.; Haque, W.; Hobbs, B.D.; Krishnan, S.; Fleming, J.B.; et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. *J. Clin. Oncol.* 2011, 29, 3037–3043. [CrossRef]

15. Ilic, M.; Ilic, I. Epidemiology of pancreatic cancer. *World J. Gastroenterol.* 2016, 22, 9694–9705. [CrossRef]

16. Ansari, D.; Tingstedt, B.; Andersson, B.; Holmqvist, F.; Sturesson, C.; Willans, P.; Sareli, A.; Bauden, M.; Andersson, R. Pancreatic cancer: Yesterday, today and tomorrow. *Future Oncol.* 2016, 12, 1929–1946. [CrossRef]

17. Collisson, E.A.; Bailey, P.; Chang, D.K.; Blankin, A.V. Molecular subtypes of pancreatic cancer. *Nat. Rev. Gastroenterol. Hepatol.* 2019, 16, 207–220. [CrossRef]

18. Huxley, R.; Ansary-Moghaddam, A.; Berrington de Gonzalez, A.; Barzi, F.; Woodward, M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. *Br. J. Cancer* 2005, 92, 2076–2083. [CrossRef]

19. Bosetti, C.; Rosato, V.; Li, D.; Silverman, D.; Petersen, G.M.; Bracci, P.M.; Neale, R.E.; Muscat, J.; Anderson, K.; Gallinger, S.; et al. Diabetes, anti-diabetic medications, and pancreatic cancer risk: An analysis from the International Pancreatic Cancer Case-Control Consortium. *Ann. Oncol.* 2014, 25, 2065–2072. [CrossRef]

20. Olson, S.H.; Xu, Y.; Herzog, K.; Salida, A.; DeFilippis, E.M.; Li, P.; Allen, P.J.; O’Reilly, E.M.; Kurtz, R.C. Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. *Pancras* 2016, 45, 986–991. [CrossRef]

21. Jeon, C.Y.; Kim, S.; Lin, Y.C.; Risch, H.A.; Goodarzi, M.O.; Nuckols, T.K.; Freedland, S.J.; Pandol, S.J.; Pise-magner, J.R. Prediction of Pancreatic Cancer in Diabetes Patients with Worsening Glycemic Control. *Cancer Epidemiol. Biomark. Prev.* 2022, 31, 242–253. [CrossRef]

22. Bodmer, M.; Becker, C.; Meier, C.; Jick, S.S.; Meier, C.R. Use of anti-diabetic medications and the risk of pancreatic cancer: A case-control analysis. *Am. J. Gastroenterol.* 2012, 107, 620–626. [CrossRef]

23. Colmers, I.N.; Bowker, S.L.; Tjosvold, L.A.; Johnson, J.A. Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. *Diabetes Metab.* 2012, 38, 485–506. [CrossRef]

24. Vaziri-Gohar, A.; Zarei, M.; Brody, J.R.; Winter, J.M. Metabolic Dependencies in Pancreatic Cancer. *Front. Oncol.* 2018, 8, 617. [CrossRef]

25. Schiliro, C.; Firestein, B.L. Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. *Cells* 2021, 10, 1056. [CrossRef]

26. Biancur, D.E.; Kimmelman, A.C. The plasticity of pancreatic cancer metabolism in tumor progression and therapeutics resistance. *Biochim. Biophys Acta Rev. Cancer* 2018, 1870, 67–75. [CrossRef]

27. Sousa, C.M.; Biancur, D.E.; Wang, X.; Halbrook, C.J.; Sherman, M.H.; Zhang, L.; Kremer, D.; Hveng, R.F.; Witkiewicz, A.K.; Ying, H.; et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. *Nature* 2016, 536, 479–483. [CrossRef]

28. Ahmad, R.S.; Eubank, T.D.; Lukomska, S.; Boone, B.A. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. *Biomolecules* 2021, 11, 901. [CrossRef]

29. Daemen, A.; Peterson, D.; Sahu, N.; McCord, R.; Du, X.; Liu, B.; Kowzanet, K.; Hong, R.; Moffat, J.; Gao, M.; et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. *Proc. Natl. Acad. Sci. USA* 2015, 112, E4410–E4417. [CrossRef]

30. Kim, J.; DeBerardinis, R.J. Mechanisms and Implications of Metabolic Heterogeneity in Cancer. *Cell Metab.* 2019, 30, 434–446. [CrossRef]

31. Bernard, V.; Semaan, A.; Huang, J.; San Lucas, F.A.; Mulu, F.C.; Stephens, B.M.; Guerrero, P.A.; Huang, Y.; Zhao, J.; Kamayabi, N.; et al. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. *Clin. Cancer Res.* 2019, 25, 2194–2205. [CrossRef] [PubMed]

32. Peng, J.; Sun, B.F.; Chen, C.Y.; Zhou, J.Y.; Chen, Y.S.; Chen, H.; Liu, L.; Huang, D.; Jiang, J.; Cui, G.S.; et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. *Cell Res.* 2019, 29, 725–738. [CrossRef] [PubMed]

33. Hausmann, S.; Kong, B.; Michalski, C.; Erkan, M.; Friess, H. The role of inflammation in pancreatic cancer. *Adv. Exp. Med. Biol.* 2014, 816, 129–151. [CrossRef] [PubMed]

34. Palisson-McDermott, E.M.; O’Neill, L.A.J. Targeting immunometabolism as an anti-inflammatory strategy. *Cell Res.* 2020, 30, 300–314. [CrossRef]

35. Cao, L.; Wu, J.; Qu, X.; Sheng, J.; Cui, M.; Liu, S.; Huang, X.; Xiang, Y.; Li, B.; Zhang, X.; et al. Glycometabolic rearrangements–aerobic glycolysis in pancreatic cancer: Characteristics, consequences and clinical applications. *J. Exp. Clin. Cancer Res.* 2020, 39, 267. [CrossRef]

36. Davidson, S.; Efremova, M.; Riedel, A.; Mahata, B.; Pramanik, J.; Huuhtanen, J.; Kar, G.; Vento-Tormo, R.; Hagai, T.; Chen, X.; et al. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. *Cell Rep.* 2020, 31, 107628. [CrossRef]
37. Assmann, N.; Finlay, D.K. Metabolic regulation of immune responses: Therapeutic opportunities. *J. Clin. Investig.* 2016, 126, 2031–2039. [CrossRef]

38. Penny, H.L.; Siew, J.L.; Gun, S.Y.; Lau, M.C.; Lee, B.; Tan, J.; Phua, H.; Toh, F.; Nga, Y.; Yeap, W.H.; et al. Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma. *Int. J. Mol. Sci.* 2021, 22, 6350. [CrossRef]

39. Sharma, N.S.; Gupta, V.K.; Garrido, V.T.; Hadad, R.; Durden, B.K.; Kesh, K.; Giri, B.; Ferrantella, A.; Dudeja, V.; Saluja, A.; et al. Targeting tumor-intrinsic hexoseamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. *J. Clin. Investig.* 2020, 130, 451–465. [CrossRef]

40. Ying, H.; Kimmel, A.C.; Lyssiotis, C.A.; Hua, S.; Chu, G.C.; Fletcher-Sananikone, E.; Locasale, J.W.; Son, J.; Zhang, H.; Coloff, J.L.; et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* 2012, 149, 656–670. [CrossRef]

41. Yun, J.; Rago, C.; Cheong, I.; Pagliarini, R.; Angenendt, P.; Rajagopalan, H.; Schmidt, K.; Willson, J.K.; Markowitz, S.; Zhou, S.; et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 2009, 325, 1555–1559. [CrossRef]

42. Lau, A.N.; Li, Z.; Danai, L.V.; Westermark, A.M.; Darnell, A.M.; Ferreira, R.; Gocheva, V.; Sivanand, S.; Lien, E.C.; Sapp, K.M.; et al. Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. *Elife* 2020, 9, e56782. [CrossRef]

43. Kurahara, H.; Maemura, K.; Mafaki, Y.; Sakoda, M.; Iino, S.; Kawasaki, Y.; Arigami, T.; Mori, S.; Kijima, Y.; Ueno, S.; et al. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Ann. Surg. Oncol.* 2018, 25, 1432–1439. [CrossRef]

44. Stopa, K.B.; Kusiak, A.A.; Szopa, M.D.; Ferdek, P.E.; Jakubowska, M.A. Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies. *Int. J. Mol. Sci.* 2020, 21, 3218. [CrossRef]

45. Cox, T.R. The matrix in cancer. *Nat. Rev. Cancer* 2021, 21, 217–238. [CrossRef]

46. Apte, M.V.; Wilson, J.S.; Lugea, A.; Pandol, S.J. A starring role for stellate cells in the pancreatic cancer microenvironment. *Gastroenterology* 2013, 144, 1210–1219. [CrossRef]

47. Korhonen, E.A.; Lampinen, A.; Giri, H.; Anisimov, A.; Kim, M.; Allen, B.; Fang, S.; Amico, G.; Sipila, T.; Lohela, M.; et al. Tie1 controls angiopeitoin 2-dependent remodeling and inflammation in SCCVII tumor. *Cancer Cell* 2020, 21, 451–465. [CrossRef]

48. Scafoglio, C.; Hirayama, B.A.; Kepe, V.; Liu, J.; Ghezzi, C.; Satyamurthy, N.; Moatamed, N.A.; Huang, J.; Koepsell, H.; Barrio, J.R.; et al. Functional expression of sodium-glucose transporters in cancer. *Proc. Natl. Acad. Sci. USA* 2015, 112, E4111–E4119. [CrossRef]

49. Karamouzis, M.V. Pancreatic ductal adenocarcinoma: A controversial issue. *Oncotarget* 2016, 7, 58649–58658. [CrossRef]

50. Nelson, J.K.; Thin, M.Z.; Evans, T.; Howell, S.; Wu, M.; Almeida, B.; Legrave, N.; Koenis, D.S.; Kofman, G.; Sugimoto, Y.; et al. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. *Nat. Commun.* 2022, 13, 2070. [CrossRef]

51. Leppanen, V.M.; Saharinen, P.; Alitalo, K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. *Proc. Natl. Acad. Sci. USA* 2017, 114, 4376–4381. [CrossRef][PubMed]

52. Inoue, M.; Hager, J.H.; Ferrara, N.; Gerber, H.P.; Hanahan, D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. *Nat. Commun.* 2014, 5, 4111–4119. [CrossRef]

53. Nelson, J.K.; Thin, M.Z.; Evans, T.; Howell, S.; Wu, M.; Almeida, B.; Legrave, N.; Koenis, D.S.; Kofman, G.; Sugimoto, Y.; et al. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. *Nat. Commun.* 2022, 13, 2070. [CrossRef][PubMed]
Cancers 2022, 14, 3799

62. Baek, G.; Tse, Y.F.; Hu, Z.; Cox, D.; Buboltz, N.; McCue, P.; Yeo, C.J.; White, M.A.; DeBerardinis, R.J.; Knudsen, E.S.; et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014, 9, 2233–2249. [CrossRef]

63. Quinn, W.J.; III; Jiao, J.; TeSlaa, T.; Stadanolick, J.; Wang, Z.; Wang, L.; Akimova, T.; Angelin, A.; Schafer, P.M.; Cully, M.D.; et al. Lactate Limits T Cell Proliferation via the NAD(H) Redox State. Cell Rep. 2020, 33, 108500. [CrossRef]

64. Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does It Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218. [CrossRef]

65. Shukla, S.K.; Purohit, V.; Mehla, K.; Gunda, V.; Chaika, N.V.; Vernucci, E.; King, R.J.; Abrego, J.; Goode, G.D.; Dasgupta, A.; et al. MUC1 and HIF-1alpha Signaling Crossstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 2017, 32, 392. [CrossRef]

66. Riethdorf, S.; Reimers, N.; Assmann, V.; Kornfeld, J.W.; Terracciano, L.; Sauter, G.; Pantel, K. High incidence of EMMPRIN expression in human tumors. Int. J. Cancer 2006, 119, 1800–1810. [CrossRef]

67. Kirk, P.; Wilson, M.C.; Heddle, C.; Brown, M.H.; Barclay, A.N.; Halestrap, A.P. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000, 19, 3896–3904. [CrossRef]

68. Schneiderhan, W.; Scheler, M.; Holzmann, K.H.; Marx, M.; Gschwend, J.E.; Bucholz, M.; Gress, T.M.; Seufferlein, T.; Adler, G.; Oswald, F. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in vivo and in vitro models. Gut 2009, 58, 1391–1398. [CrossRef]

69. Patra, K.C.; Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 2014, 39, 347–354. [CrossRef]

70. Bechard, M.E.; Word, A.E.; Tran, A.V.; Liu, X.; Locasale, J.W.; McDonald, O.G. Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. Oncogene 2018, 37, 5248–5256. [CrossRef]

71. Kruger, N.J.; von Schaewen, A. The oxidative pentose phosphate pathway: Structure and organisation. Curr. Opin. Plant. Biol. 2003, 6, 236–246. [CrossRef]

72. Stincone, A.; Prigione, A.; Cramer, T.; Wamelink, M.M.; Campbell, K.; Cheung, E.; Gruning, N.M.; Kruger, A.; Tauerqer Alam, M.; et al. The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biochim. Biophys. Acta 2015, 90, 927–963. [CrossRef]

73. Santana-Codina, N.; Roeth, A.A.; Zhang, Y.; Yang, A.; Mashadova, O.; Asara, J.M.; Wang, X.; Bronson, R.T.; Lyssiotis, C.A.; Ying, H.; et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat. Commun. 2018, 9, 4945. [CrossRef]

74. Yang, Y.; Ishak Gabra, M.B.; Hanse, E.A.; Lowman, X.H.; Tran, T.Q.; Li, H.; Milman, N.; Liu, J.; Reid, M.A.; Locasale, J.W.; et al. MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. Nat. Commun. 2019, 10, 809. [CrossRef]

75. Wu, D.H.; Liang, H.; Lu, S.N.; Wang, H.; Su, Z.L.; Zhang, L.; Ma, J.Q.; Guo, M.; Tai, S.; Yu, S. MiR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism. Cell Physiol. Biochem. 2018, 50, 924–935. [CrossRef]

76. Abue, M.; Yokoyama, M.; Shibuya, R.; Tamai, K.; Yamaguchi, K.; Sato, I.; Tanaka, N.; Hamada, S.; Shimosegawa, T.; Sugamura, K.; et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer patients. Cancer Sci. 2019, 110, 1487–1495. [CrossRef]

77. Daoud, A.Z.; Mulholland, E.J.; Cole, G.; McCarthy, H.O. MicroRNAs in Pancreatic Cancer: Biomarkers, prognostic, and therapeutic modulators. BMC Cancer 2019, 19, 1130. [CrossRef]

78. Xu, R.; Yang, J.; Ren, B.; Wang, H.; Yang, G.; Chen, Y.; You, L.; Zhao, Y. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Front. Oncol. 2020, 10, 572272. [CrossRef]

79. Cruzat, V.; Macedo Rogero, M.; Noël Keane, K.; Curi, R.; Newsholme, P. Glutamine: Metabolism and Immune Function, 68. Schneiderhan, W.; Scheler, M.; Holzmann, K.H.; Marx, M.; Gschwend, J.E.; Bucholz, M.; Gress, T.M.; Seufferlein, T.; Adler, G.; Oswald, F. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in vivo and in vitro models. Gut 2009, 58, 1391–1398. [CrossRef]

80. Stincone, A.; Prigione, A.; Cramer, T.; Wamelink, M.M.; Campbell, K.; Cheung, E.; Gruning, N.M.; Kruger, A.; Tauerqer Alam, M.; et al. The return of metabolism: Biochemistry and physiology of the pentose phosphate pathway. Biochim. Biophys. Acta 2015, 90, 927–963. [CrossRef]

81. Cluntun, A.A.; Lukey, M.J.; Cerione, R.A.; Locasale, J.W. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer 2017, 3, 169–180. [CrossRef] [PubMed]

82. Kamphorst, J.J.; Nofal, M.; Commissio, C.; Hackett, S.R.; Lu, W.; Grabocka, E.; Vander Heiden, M.G.; Miller, G.; Drebin, J.A.; Bar-Sagi, D.; et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015, 75, 544–553. [CrossRef]

83. Bott, A.J.; Shen, J.; Tonelli, C.; Zhan, L.; Sivaram, N.; Jiang, Y.P.; Yu, X.; Bhatt, V.; Chiles, E.; Zhong, H.; et al. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Rep. 2019, 29, 1287–1298. [CrossRef] [PubMed]

84. Reyes-Castellanos, G.; Abdel Hadi, N.; Carrier, A. Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors. Cells 2020, 9, 1164. [CrossRef]

85. Wu, D.H.; Liang, H.; Lu, S.N.; Wang, H.; Su, Z.L.; Zhang, L.; Ma, J.Q.; Guo, M.; Tai, S.; Yu, S. MiR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism. Cell Physiol. Biochem. 2018, 50, 924–935. [CrossRef]

86. Commisso, C.; Davidson, S.M.; Soydaner-Azeloglu, R.G.; Parker, S.J.; Kamphorst, J.J.; Hackett, S.; Grabocka, E.; Nofal, M.; Drebin, J.A.; Thompson, C.B.; et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497, 633–637. [CrossRef] [PubMed]

87. Wise, D.R.; DeBerardinis, R.J.; Mancuso, A.; Sayed, N.; Zhang, X.Y.; Pfeiffer, H.K.; Nissim, I.; Dakhin, E.; Yudkoff, M.; McMahon, S.B.; et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 2008, 105, 18782–18787. [CrossRef] [PubMed]
Cancers 2022, 14, 3799

114. Dalen, K.T.; Ulven, S.M.; Arnsen, B.M.; Solaas, K.; Nebb, H.I. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. J. Lipid Res. 2006, 47, 931–943. [CrossRef]

115. Chang, B.H.; Li, L.; Paul, A.; Taniguchi, S.; Nanegari, V.; Heird, W.C.; Chan, L. Protection against fatty liver by normal adipogenesis in mice lacking adipose differentiation-related protein. Mol. Cell Biol. 2006, 26, 1063–1076. [CrossRef]

116. Hashimoto, Y.; Ishida, M.; Ryota, H.; Yamamoto, T.; Kosaka, H.; Hirooka, S.; Yamaki, S.; Kotsuka, M.; Matsui, Y.; Yanagimoto, H.; et al. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Pancreatology 2019, 19, 443–448. [CrossRef]

117. Chen, E.; Tsai, T.H.; Li, L.; Saha, P.; Chan, L.; Chang, B.H. PLIN2 is a Key Regulator of the Unfolded Protein Response and Endoplasmic Reticulum Stress Resolution in Pancreatic beta Cells. Sci. Rep. 2017, 7, 40855. [CrossRef]

118. Schmidt, S.M.; Schag, K.; Muller, M.R.; Weisenschien, T.; Appel, S.; Schoor, O.; Weck, M.M.; Grunebach, F.; Kanz, L.; Stevanovic, S.; et al. Induction of adipophilin expression in pancreatic cancer using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 2004, 64, 1164–1170. [CrossRef]

119. Seifert, A.M.; Reiche, C.; Heituk, M.; Tannert, A.; Meinecke, A.C.; Baier, S.; von Renesse, J.; Kahlert, C.; Distler, M.; Welsch, T.; et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene 2020, 39, 3102–3113. [CrossRef]

120. He, Y.; Dong, Y.; Zhang, X.; Ding, Z.; Song, Y.; Huang, X.; Chen, S.; Wang, Z.; Ni, Y.; Ding, L. Lipid Droplet-Related PLIN2 in CD68(+) Tumor-Associated Macrophage of Oral Squamous Cell Carcinoma: Implications for Cancer Prognosis and Immunotherapy. Front. Oncol. 2022, 12, 824235. [CrossRef]

121. Philip, B.; Roland, C.L.; Daniluk, J.; Liu, Y.; Chatterjee, D.; Gomez, S.B.; Ji, B.; Huang, H.; Wang, H.; Fleming, J.B.; et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013, 145, 1449–1458. [CrossRef]

122. Chung, K.M.; Singh, J.; Lawres, L.; Dorans, K.J.; Garcia, C.; Burkhardt, D.B.; Robbins, R.; Blutkar, A.; Cardone, R.; Zhao, X.; et al. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell 2020, 181, 832–847.E18. [CrossRef]

123. Greenberg, A.S.; Coleman, R.A.; Kraemer, F.B.; McManaman, J.L.; Obin, M.S.; Puri, V.; Yan, Q.W.; Miyoshi, H.; Mashek, D.G. The role of lipid droplets in metabolic disease in rodents and humans. J. Clin. Investig. 2011, 121, 2102–2110. [CrossRef]

124. Olzmann, J.A.; Carvalho, P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 2019, 20, 137–155. [CrossRef]

125. Guillaumond, F.; Bidaut, G.; Ouaisi, M.; Servais, S.; Gouirand, V.; Olivares, O.; Lac, S.; Borge, L.; Roques, J.; Gayet, O.; et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 2015, 112, 2473–2478. [CrossRef]

126. Kamp, F.; Hamilton, J.A. How fatty acids of different chain length enter and leave cells by free diffusion. Proc. Natl. Acad. Sci. USA 2013, 110, 8882–8887. [CrossRef]

127. Padanad, M.S.; Konstantinidou, G.; Venkateswaran, N.; Melegari, M.; Rindhe, S.; Mitsche, M.; Yang, C.; Batten, K.; Huffman, K.E.; Liu, J.; et al. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep. 2016, 16, 1614–1628. [CrossRef]

128. Kamp, F.; Hamilton, J.A. How fatty acids of different chain length enter and leave cells by free diffusion. Prostaglandins Leukot Essent Fat Acids 2006, 75, 149–159. [CrossRef]

129. Rossi Sebastiano, M.; Konstantinidou, G. Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy. Int. J. Mol. Sci. 2019, 20, 3624. [CrossRef]

130. Saliakoura, M.; Sebastiano, M.R.; Nikdima, I.; Pozzato, C.; Konstantinidou, G. Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy. J. Exp. Clin. Cancer Res. 2022, 41, 16. [CrossRef]

131. Brandi, J.; Dando, I.; Pozza, E.D.; Biondani, G.; Jenkins, R.; Elliott, V.; Park, K.; Fanelli, G.; Zolla, L.; Costello, E.; et al. Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. J. Proteomics 2017, 150, 310–322. [CrossRef] [PubMed]

132. Di Carlo, C.; Sousa, B.C.; Manfredi, M.; Brandi, J.; Dalla Pozza, E.; Marengo, E.; Palmieri, M.; Dando, I.; Wakelam, M.J.O.; Lopez-Clavijo, A.F.; et al. Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells. Sci. Rep. 2021, 11, 13297. [CrossRef] [PubMed]

133. El-Hafidi, M.; Correa, F.; Zazueta, C. Mitochondrial dysfunction in metabolic and cardiovascular diseases associated with cardiolipin remodeling. Biochim. Biophys. Acta. Mol. Basis Dis. 2020, 1866, 16574. [CrossRef] [PubMed]

134. Pfeiffer, K.; Gohil, V.; Stuart, R.A.; Hunte, C.; Brandt, U.; Greenberg, M.L.; Schagger, H. Cardiolipin stabilizes respiratory chain supercomplexes. J. Biol. Chem. 2003, 278, 52873–52880. [CrossRef]

135. Wolrab, D.; Jirasko, R.; Cifkova, E.; Horing, M.; Mei, D.; Chocholouskova, M.; Peterka, O.; Idkowiak, J.; Hrnciarova, T.; Kuchar, T.; et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat. Commun. 2022, 13, 124. [CrossRef]

136. Mayerle, J.; Kalthoff, H.; Reszka, R.; Kamlage, B.; Peter, E.; Schniewind, B.; Gonzalez Maldonado, S.; Pilarsky, C.; Heidecke, C.D.; Schatz, P.; et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 2018, 67, 128–137. [CrossRef]

137. Fahrmann, J.F.; Bantie, L.E.; Capello, M.; Scollo, G.; Demnison, J.B.; Patel, N.; Murage, E.; Vykoukal, J.; Kundnani, D.L.; Foretova, L.; et al. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J. Natl. Cancer Inst. 2019, 111, 372–379. [CrossRef]
138. Wang, G.; Yao, H.; Gong, Y.; Lu, Z.; Pang, R.; Li, Y.; Yuan, Y.; Song, H.; Liu, J.; Jin, Y.; et al. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Sci. Adv. 2021, 7, eabf2724. [CrossRef]

139. Macias, R.I.R.; Munoz-Bellvis, L.; Sanchez-Martin, A.; Arretxe, E.; Martinez-Arranz, I.; Lapitz, A.; Gutierrez, M.L.; La Casta, A.; Alonso, C.; Gonzalez, L.M.; et al. A Novel Serum Metabolomic Profile for the Differentiation of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers 2020, 12, 1433. [CrossRef]

140. Doll, S.; Proneth, B.; Tyurina, Y.Y.; Panzilussi, E.; Kobayashi, S.; Ingold, I.; Irmler, M.; Beckers, J.; Aichler, M.; Walch, A.; et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017, 13, 91–98. [CrossRef]

141. Hu, N.; Bai, L.; Dai, E.; Han, L.; Kang, R.; Li, H.; Tang, D. Pirin is a nuclear redox-sensitive modulator of autophagy-dependent ferroptosis. Biochem. Biophys. Res. Commun. 2021, 536, 100–106. [CrossRef]

142. Okawa, T.; Nagai, M.; Hase, K. Dietary Intervention Impacts Immune Cell Functions and Dynamics by Inducing Metabolic Rewiring. Front. Immunol. 2020, 11, 623989. [CrossRef]

143. Loftus, R.M.; Finlay, D.K. Immunometabolism: Cellular Metabolism Turns Immune Regulator. J. Biol. Chem. 2016, 291, 1–10. [CrossRef]

144. Chang, C.H.; Gou, J.; O’Sullivan, D.; Buck, M.D.; Noguchi, T.; Curtis, J.D.; Chen, Q.; Gindin, M.; Gubin, M.M.; van der Windt, G.J.; et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 2015, 162, 1229–1241. [CrossRef]

145. Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Sato, N.; Ochiai, A.; Tomita, M.; et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69, 4918–4925. [CrossRef]

146. Ochi, A.; Nguyen, A.H.; Bedrosian, A.S.; Mushlin, H.M.; Zarbakhsh, S.; Barilla, R.; Zambirinis, C.P.; Fallon, N.C.; Rehm, A.; Pyleavea-Gupta, Y.; et al. MDY8 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 2012, 209, 1671–1687. [CrossRef]

147. Choi, S.Y.; Collins, C.C.; Gout, P.W.; Wang, Y. Cancer-generated lactic acid: A regulatory, immunosuppressive metabolite? J. Pathol. 2013, 230, 350–355. [CrossRef]

148. Fukunaga, A.; Miyamoto, M.; Cho, Y.; Murakami, S.; Kawarada, Y.; Oshikiri, T.; Kato, K.; Kurokawa, T.; Suzuki, M.; Nakakubo, Y.; et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Panncreas 2004, 28, e26–e31. [CrossRef]

149. Ino, Y.; Yamazaki-Itoh, R.; Shimada, K.; Iwasaki, M.; Kanai, Y.; Hiraoka, N. Immune cell infiltration as an indicator of prognosis in patients with pancreatic ductal adenocarcinoma. Cancer Sci. 2014, 105, 1196–1202. [CrossRef]

150. Kim, J.S.; Park, Y.S.; Kim, J.Y.; Kim, Y.G.; Kim, Y.J.; Lee, H.K.; Kim, H.S.; Hong, J.T.; Kim, Y.; Han, S.B. Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model. Immune. Netw. 2012, 12, 247–252. [CrossRef]

151. Yamamoto, K.; Venida, A.; Yano, J.; Biancur, D.E.; Kakiuchi, M.; Gupta, S.; Sohn, A.S.W.; Mukhopadhyay, S.; Lin, E.Y.; Parker, S.J.; et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 2020, 581, 100–105. [CrossRef]

152. Liu, L.; Zhao, G.; Wu, W.; Rong, Y.; Jin, D.; Wang, D.; Lou, W.; Qin, X. Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy. Cancer Immunol. Immunother. 2016, 65, 73–82. [CrossRef]

153. Kurts, C. Th17 cells: A third subset of CD4+ T effector cells involved in organ-specific autoimmune disease. Nephrol. Dial. Transplant. 2008, 23, 816–819. [CrossRef] [PubMed]

154. Wormann, S.M.; Diakopoulos, K.N.; Lesina, M.; Algul, H. The immune network in pancreatic cancer development and progression. Oncogene 2014, 33, 2956–2967. [CrossRef] [PubMed]

155. Gnerlich, J.L.; Mitchem, J.B.; Weir, J.S.; Sankpal, N.V.; Kashiwagi, H.; Belt, B.A.; Porembka, M.R.; Herndon, J.M.; Eberlein, T.J.; Goedegebuure, P.; et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 2010, 185, 4063–4071. [CrossRef]

156. Helderman, J.H.; Reynolds, T.C.; Strom, T.B. The insulin receptor as a universal marker of activated lymphocytes. Eur. J. Immunol. 1978, 8, 589–595. [CrossRef] [PubMed]

157. Fischer, H.J.; Sie, C.; Schumann, E.; Witte, A.K.; Dressel, R.; van den Brandt, J.; Reichardt, H.M. The Insulin Receptor Plays a Critical Role in T Cell Function and Adaptive Immunity. J. Immunol. 2017, 198, 1910–1920. [CrossRef] [PubMed]

158. Singer, K.; Cheng, W.C.; Kreutz, M.; Ho, P.C.; Siska, P.J. Immunometabolism in cancer at a glance. Dis. Model. Mech. 2018, 11, dmm034272. [CrossRef]

159. Sinclair, L.V.; Rolf, J.; Emslie, E.; Shi, Y.B.; Taylor, P.M.; Cantrell, D.A. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 2013, 14, 500–508. [CrossRef]

160. Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusiec, E.; Frederick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 2012, 109, 2497–2502. [CrossRef]

161. Yamamoto, T.; Yanagimoto, H.; Satoi, S.; Toyokawa, H.; Hirooka, S.; Yamaki, S.; Yui, R.; Yamao, J.; Kim, S.; Kwon, A.H. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012, 41, 409–415. [CrossRef]

162. Cai, S.W.; Yang, S.Z.; Gao, J.; Pan, K.; Chen, J.Y.; Wang, Y.L.; Wei, L.X.; Dong, J.H. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 2011, 149, 576–584. [CrossRef]

163. Deicher, A.; Andersson, R.; Tingstedt, B.; Lindell, G.; Bauden, M.; Ansari, D. Targeting dendritic cells in pancreatic ductal adenocarcinoma. Cancer Cell Int. 2018, 18, 85. [CrossRef]
164. Dietl, K.; Renner, K.; Dettmer, K.; Timischl, B.; Eberhart, K.; Dorn, C.; Hellerbrand, C.; Kastenberger, M.; Kunz-Schughart, L.A.; Oefner, P.J.; et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. *J. Immunol.* **2010**, *184*, 1200–1209. [CrossRef]

165. Yang, S.; Liu, Q.; Liao, Q. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. *Front. Cell Dev. Biol.* **2020**, *8*, 607209. [CrossRef]

166. Mills, E.L.; O’Neill, L.A. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. *Eur. J. Immunol.* **2016**, *46*, 13–21. [CrossRef]

167. Rodriguez-Prados, J.C.; Traves, P.G.; Cuenca, J.; Rico, D.; Aragones, J.; Martin-Sanz, P.; Cascante, M.; Bosca, L. Substrate fate in activated macrophages: A comparison between innate, classic, and alternative activation. *J. Immunol.* **2010**, *185*, 605–614. [CrossRef]

168. Haschemi, A.; Kosma, P.; Gille, L.; Evans, C.R.; Burant, C.F.; Starkl, P.; Knapp, B.; Haas, R.; Schmid, J.A.; Jandl, C.; et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. *Cell Metab.* **2012**, *15*, 813–826. [CrossRef]

169. O’Neill, L.A.; Kishton, R.J.; Rathmell, J. A guide to immunometabolism for immunologists. *Nat. Rev. Immunol.* **2016**, *16*, 553–565. [CrossRef]

170. Amedei, A.; Niccolai, E.; Prisco, D. Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. *Hum. Vaccin. Immunother.* **2014**, *10*, 3354–3368. [CrossRef]

171. De Monte, L.; Reni, M.; Tassi, E.; Clavenna, D.; Papa, I.; Recalde, H.; Braga, M.; Di Carlo, V.; Doglioni, C.; Protti, M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. *J. Exp. Med.* **2011**, *208*, 469–478. [CrossRef] [PubMed]

172. O’Sullivan, D.; van der Windt, G.J.; Huang, S.C.; Curtis, J.D.; Chang, C.H.; Buck, M.D.; Qiu, J.; Smith, A.M.; Lam, W.Y.; DiPlato, L.M.; et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. *Immunity* **2014**, *41*, 75–88. [CrossRef] [PubMed]

173. Esposito, I.; Menicagli, M.; Funel, N.; Bergmann, F.; Boggi, U.; Mosca, F.; Bevilacqua, G.; Campani, D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. *J. Clin. Pathol.* **2004**, *57*, 630–636. [CrossRef] [PubMed]

174. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. *Science* **2009**, *324*, 1029–1033. [CrossRef]

175. Arnold, C.; Demuth, P.; Seiwert, N.; Wittmann, S.; Boengler, K.; Rasenberger, B.; Christmann, M.; Huber, M.; Brunner, T.; Linnebacher, M.; et al. The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. *Mol. Cancer Ther.* **2022**, *21*, 100–112. [CrossRef]

176. Rebelo, R.; Polonia, B.; Santos, L.L.; Vasconcelos, M.H.; Xavier, C.P.R. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. *Pharmaceuticals* **2021**, *14*, 280. [CrossRef]

177. Islam, M.M.; Goertzen, A.; Singh, P.K.; Saha, R. Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. *iScience* **2022**, *25*, 104483. [CrossRef]